Duke University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Duke University sits in the top decile of US sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count).

1,725 total trials 187 currently recruiting 1244 completed early-phase tilt top decile by trial count

Duke University: 1,725 sponsored US clinical trials, 187 recruiting.

Duke University sponsors 1,725 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 1,244 completed. 175 of these trials are in Phase 3-4 (later-stage) and 311 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.

Top-decile sponsor footprint

Duke University ranks in the top decile of sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 55/100

1,244 of 1,444 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,725 total, page 27 of 35

COMPLETED NA

ENLIGHTEN: Exercise and NutritionaL Interventions for coGnitive and Cardiovascular HealTh ENhancement

NCT01573546

COMPLETED NA

Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method

NCT02025413

COMPLETED

Magnetic Resonance Imaging (MRI) in Motion

NCT02019199

COMPLETED

Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes

NCT01377688

COMPLETED NA

Prospective Randomized Evaluation of a Two and Three Piece Total Ankle Replacement

NCT01504438

COMPLETED

Vasospasm in Pediatric Traumatic Brain Injury

NCT01461902

COMPLETED NA

New Therapy for Patients With Severe Tinnitus

NCT01480193

COMPLETED

Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment

NCT01727440

COMPLETED

Improving Emergency Department Management of Adults With Sickle Cell Disease

NCT01603160

COMPLETED

RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol

NCT01406210

TERMINATED

Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip

NCT01759550

TERMINATED Phase 4

Right Ventricular (RV) Pacing in Early Post-operative Continuous Flow Left Ventricular Assist Device (LVAD)

NCT01446796

COMPLETED NA

Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants

NCT01431300

COMPLETED Phase 2

Meclizine as a Potential Smoking Cessation Treatment

NCT01443858

COMPLETED Phase 4

Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)

NCT01450800

TERMINATED Phase 2

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

NCT01207102

COMPLETED NA

Patient and Provider Interventions for Managing Osteoarthritis in Primary Care

NCT01435109

COMPLETED NA

Feasibility of a Stigma Reduction Intervention for Human Immunodeficiency Virus (HIV)-Infected Women

NCT01385241

COMPLETED Phase 3

Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation

NCT01406223

COMPLETED Phase 3

Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial

NCT01829243

COMPLETED Phase 2

Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo

NCT01419977

COMPLETED Phase 1

Statin Therapy to Improve Medication Adherence

NCT01894217

COMPLETED Phase 2

Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia

NCT02151253

COMPLETED NA

Mindfulness-based Personalized Health Planning for Reducing Risk of Heart Disease and Diabetes

NCT01430221

TERMINATED Phase 2

Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia

NCT01309659

COMPLETED Phase 1

Sildenafil in Single Ventricle Patients

NCT01169519

COMPLETED NA

Mila Blooms Intervention Study

NCT01473342

COMPLETED NA

Cognitive Behavioral Treatments for Depression in Chronic Illness

NCT01208428

COMPLETED NA

A Novel Optical Spectral Imaging System for Imaging Breast Tumor Margins

NCT01372631

TERMINATED Phase 2

Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

NCT01186406

COMPLETED Phase 3

Concurrent Bupropion / Varenicline for Smoking Cessation

NCT01303861

TERMINATED NA

Patient Positioning in Lumbar Fusion Surgery and Its Impact on Spinal Sagittal Balance and Surgeon Satisfaction

NCT01326091

COMPLETED Phase 2

Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection

NCT01191840

COMPLETED

Impact of Blood Storage Duration on Physiologic Measures

NCT01274390

COMPLETED NA

Steps to Health: Targeting Obesity in the Health Care Workplace

NCT01299051

COMPLETED NA

Ehealth: Second Life Impacts Diabetes Education & Self-Management

NCT01186965

TERMINATED NA

Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial)

NCT01169493

COMPLETED Phase 4

Open Label Use Of RiaStap During Aortic Reconstruction

NCT01300286

COMPLETED NA

Personalized Cardiovascular Risk Information to Initiate and Maintain Health Behavior Changes

NCT01134458

COMPLETED

The Effects of Respiratory Muscle Strength Training (RMST) on Inspiratory and Expiratory Muscle Strength in Adults and Children With Pompe Disease

NCT01701154

TERMINATED NA

Early Intervention for Morbidly Obese Patients After Roux-en-Y Gastric Bypass (RYGB) Surgery

NCT01329692

COMPLETED

Educational Videos to Improve Patient Decision Making and Race Disparities in Implantable Cardioverter Defibrillator Use

NCT00918125

COMPLETED NA

Cell Phone Intervention in Young Adults

NCT01092364

COMPLETED NA

Intervention Study of Communication in Oncologist-Patient Encounters

NCT00994578

COMPLETED Phase 4

Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)

NCT01780389

COMPLETED NA

Cognitive Remediation in 22q11DS

NCT01781923

COMPLETED NA

Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma

NCT01186978

COMPLETED NA

Stress Reduction Training to Improve Sleep Quality, Stress Physiology & Cardiovascular Disease (CVD) Risk Markers

NCT01343810

COMPLETED Phase 2

Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

NCT01108445

TERMINATED Phase 3

Esmolol for Treatment of Perioperative Tachycardia

NCT01208402

← Previous Page 27 of 35 Next →

Phase Distribution

PhaseTrial count
Phase 1 136
Phase 2 175
Phase 3 41
Phase 4 134

What is open in the Duke University pipeline

187 recruiting of 1,725 indexed (11% open); 1,244 completed (72%).

Phase mix: 175 late (III/IV) vs 311 early (I/II) (early-phase heavy).

Top condition: Obesity (15 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Duke University: open-pipeline peers nationwide

Peers matched on 1,725 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Duke UniversityUniversity of California, San FranciscoStanford UniversityVA Office of Research and DevelopmentPfizerCarnegie Mellon UniversityCAMC Health SystemUConn HealthHartford Hospital
Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,725 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

What to do with this Duke University page

1,725 registered trials is a research-attention snapshot, not an endorsement of Duke University or any single study.

  • 187 of Duke University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition Duke University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Duke University pipeline card: 1,725 registered trials from official public datasets.Report a data error.